|

ZG006 Clinical Trials

8 actively recruiting trials across 1 location

No change since May 2026

Pipeline

Phase 1: 2Phase 3: 1Phase 1/2: 5

Top Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd8

Indications

Cancer8
Lung Cancer7
Small Cell Lung Cancer6
Neuroendocrine Carcinoma3
Neuroendocrine Cancer1

Other7 trials

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Phase 1/2

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Phase 1/2

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Phase 3

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Phase 1

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Phase 1/2

Study of ZGGS34 in Participants With Advanced Solid Tumors

Phase 1/2

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Phase 1/2

Orange, California1 trial

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

Zelgen Site 105

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.